GeoVax Labs, Inc
GeoVax Labs, Inc. is a clinical-stage biotechnology company dedicated to developing vaccines and immunotherapies against infectious diseases and cancers. Their mission is to improve lives worldwide through innovative solutions, with a focus on unmet medical needs, expedited registration pathways, and global collaboration. They are currently conducting clinical trials for a COVID-19 vaccine (GEO-CM04S1) and a therapy for head and neck cancer (Gedeptin®), along with other programs targeting diseases like Mpox, smallpox, Ebola, Marburg, malaria, and Zika virus.
Industries
Nr. of Employees
small (1-50)
GeoVax Labs, Inc
Products
Clinical-stage therapeutic vaccine for head and neck cancer (oncology immunotherapy)
A therapeutic immunotherapy candidate in early-stage human clinical trials for advanced head and neck cancers, developed to be used alone or in combination with other cancer therapies.
Next-generation multi-antigen COVID-19 vaccine (clinical-stage)
A multi-antigen COVID-19 vaccine candidate in clinical development, evaluated as a heterologous booster and in trials targeting high-risk and immunocompromised populations.
Preclinical multivalent hemorrhagic fever and Lassa vaccine program (MVA-VLP tetravalent approach)
A preclinical program developing monovalent and potentially blended multivalent vaccines against Ebola (Zaire), Sudan, Marburg and Lassa fever using an MVA-expressed VLP platform to induce both antibody and T-cell responses.
Clinical-stage therapeutic vaccine for head and neck cancer (oncology immunotherapy)
A therapeutic immunotherapy candidate in early-stage human clinical trials for advanced head and neck cancers, developed to be used alone or in combination with other cancer therapies.
Next-generation multi-antigen COVID-19 vaccine (clinical-stage)
A multi-antigen COVID-19 vaccine candidate in clinical development, evaluated as a heterologous booster and in trials targeting high-risk and immunocompromised populations.
Preclinical multivalent hemorrhagic fever and Lassa vaccine program (MVA-VLP tetravalent approach)
A preclinical program developing monovalent and potentially blended multivalent vaccines against Ebola (Zaire), Sudan, Marburg and Lassa fever using an MVA-expressed VLP platform to induce both antibody and T-cell responses.
Services
R&D collaborations and partnering for vaccine development
Collaborative research, co-development and partnership arrangements for advancing vaccine candidates from preclinical studies through clinical development and regulatory interactions.
R&D collaborations and partnering for vaccine development
Collaborative research, co-development and partnership arrangements for advancing vaccine candidates from preclinical studies through clinical development and regulatory interactions.
Expertise Areas
- Clinical trial management for vaccines and immunotherapies
- Viral vector vaccine platform development
- Antigen design and molecular engineering
- Preclinical challenge and efficacy testing
Key Technologies
- MVA viral vector platforms
- In vivo virus-like particle (VLP) expression
- Multivalent/monovalent vaccine design
- Promoter engineering and codon optimization